Blood-Derived Extracellular Vesicles as a Promising Liquid Biopsy Diagnostic Tool for Early Cancer Detection

TL;DR

This paper explores using blood-derived extracellular vesicles as a non-invasive, cost-effective method for early cancer detection through liquid biopsy.

Contribution

The novelty lies in evaluating blood-derived extracellular vesicles as a practical tool for early cancer diagnosis.

Findings

Extracellular vesicles contain biological components useful for cancer detection.

Liquid biopsy using EVs could offer a non-invasive alternative to traditional methods.

Refining EV isolation techniques is critical for clinical implementation.

Abstract

Cancer poses a significant public health challenge worldwide, and timely screening has the potential to mitigate cancer progression and reduce mortality rates. Currently, early identification of most tumors relies on imaging techniques and tissue biopsies. However, the use of low-cost, highly sensitive, non-invasive detection methods for early cancer screening has become more attractive. Extracellular Vesicles (EVs) released by all living cells contain distinctive biological components, such as nucleic acids, proteins, and lipids. These vesicles play crucial roles in the tumor microenvironment and intercellular communication during tumor progression, rendering liquid biopsy a particularly suitable method for diagnosis. Nevertheless, challenges related to purification methods and validation of efficacy currently hinder its widespread clinical implementation. These limitations underscore the importance of refining isolation techniques and conducting comprehensive investigations on EVs. This study seeks to evaluate the potential of liquid biopsy utilizing blood-derived EVs as a practical, cost-effective, and secure approach for early cancer detection.

Figures